Digital Therapeutic Based Randomized Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy: Rationale, Design, and Baseline Characteristics of the BRIGHT Trial
Open Access
- 5 August 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e038737
Abstract
Background: The prevalence of type 2 diabetes continues to rise in the United States and worldwide. Although novel pharmacotherapies have shown benefits, not all patients have access to these medications and of those who do, some are unable to tolerate treatment. Behavior change is long known to be foundational for patients with cardiometabolic disease due to its direct positive impact on health outcomes. Cognitive behavioral therapy delivered by a digital therapeutic has the potential to address access to behavioral therapy for patients with type 2 diabetes. Methods: The BRIGHT (Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy) Trial (NCT05266625) is a randomized, controlled, multicenter, pragmatic, pivotal trial with open‐label extension evaluating the hypothesis that AspyreRx improves glycemic control and cardiometabolic measures in patients with type 2 diabetes compared with a control application added to usual care across a broad range of patients in a real‐world setting. The current study objectives are to evaluate the efficacy and safety of AspyreRx at 90 and 180 days compared with a control group and to assess the long‐term effectiveness, safety, and impact on health care and medication use over long‐term follow up. Conclusions: The AspyreRx digital therapeutic is a Food and Drug Administration approved therapy for patients with type 2 diabetes. Although its efficacy for lowering hemoglobin A1C at 90 days was demonstrated, opportunities remain to better understand the long‐term effects and the effectiveness and safety in a broader and more diverse real‐world environment. BRIGHT is designed to evaluate these questions using a virtual, decentralized, model and include a diverse site mix designed to better understand real‐world effectiveness and generalizability.Keywords
This publication has 19 references indexed in Scilit:
- Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 DiabetesAdvances in Therapy, 2024
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 DiabetesDiabetes Therapy, 2023
- Patient-reported outcome measures for assessing health-related quality of life in people with type 2 diabetes: A systematic reviewReviews in Endocrine and Metabolic Disorders, 2022
- Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trialClinical Cardiology, 2022
- Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working GroupDiabetologia, 2019
- Change in Testing, Awareness of Hemoglobin A1c Result, and Glycemic Control in US Adults, 2007-2014JAMA, 2017
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participantsThe Lancet, 2016
- The global implications of diabetes and cancerThe Lancet, 2014
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009